Cancer is a dynamic disease and during its course, cells become more heterogeneous or diverse.
A tumour may contain several sub-populations of cells and not all of these populations may be responsive to matching targeted therapy which makes delivery of precision cancer treatment problematic. With this challenge in mind, we are focusing on:
- understanding the mechanisms of cancer genome instability (genetic mutations) which drive tumour heterogeneity
- exploiting the diversity of tumour cells in an attempt to determine their response to therapy, thereby enhancing individualised treatment options
- investigating the development of resistance to targeted therapy
